Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Lytix Biopharma AS ( (DE:6BG) ) just unveiled an announcement.
Lytix Biopharma AS is set to release its second quarter 2025 financial results on August 28th, 2025, with a live webcast presentation featuring CEO Øystein Rekdal and CFO Gjest Breistein. The event will provide insights into the company’s financial performance and its implications for stakeholders, with a Q&A session to address audience questions. A recording of the presentation will be available post-event, offering stakeholders continued access to the company’s strategic insights.
More about Lytix Biopharma AS
Lytix Biopharma AS is a clinical-stage biotech company based in Oslo, Norway, specializing in immuno-oncology. The company focuses on developing novel host-defense peptide-derived molecules, with its lead product, LTX-315, being a first-in-class oncolytic molecule aimed at enhancing anti-cancer immunity. Lytix Biopharma’s pipeline includes molecules applicable in various cancer indications and treatment settings, both as mono- and combination therapies.
Average Trading Volume: 79,645
Current Market Cap: NOK622.5M
Learn more about 6BG stock on TipRanks’ Stock Analysis page.